On March 2, 2026 Precision Biologics, Inc. CEO Philip M. Arlen, MD, reported it will discuss discovery and development of tumor-specific monoclonal antibodies (mAb) in "Discovery and Development of Monoclonal Antibodies Targeting Tumor Specific Neoepitopes" at the Festival of Biologics USA, San Diego Convention Center, San Diego, CA, March 4-5, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"What is unique about our monoclonal antibodies (mAb) is that their targets are found on a broad variety of human solid tumors but not on most healthy tissue. Most anticancer drugs target proteins overexpressed on tumor tissue but also expressed in lower levels on normal tissue. Creating anticancer drugs that are not only sensitive, but specific to the tumor provides an opportunity to develop effective therapy with fewer side effects."

"We’re expanding awareness in the scientific community of these cancer-specific targets that Precision Biologics drugs can recognize that are found on various human cancers," said Dr. Arlen.

Here are details of the presentation:

Title:

"Discovery and Development of Monoclonal Antibodies Targeting Tumor Specific Neoepitopes"

Date/Time:

March 5, 2026 – Day 2, 12:20pm – Armed Antibodies Session

Place:

Festival of Biologics USA, San Diego Convention Center, San Diego, CA

Speaker:

Philip M. Arlen, M.D., President & CEO, Precision Biologics, Inc.

(Press release, Precision Biologics, MAR 2, 2026, View Source [SID1234663193])